bluuebunny/crossref_metadata_2025_split huggingface dataset:
Variation in DNA content of immature normal bone marrow cells
Authors: Widell S. , Auer G. , Hast R. , Reizenstein P. 
Published: February 2007

AbstractA variability in DNA content detected was found with image cytometry, in immature bone marrow cells from 13 healthy donors (median age 31 yr). The mean coefficient of variation (C.V.) of the DNA content was found to be significantly (P = 0.0002) higher in immature blasts and promyelocytes than in mature granulocytes, lymphocytes, and monocytes. The finding was not due to high DNA contents secondary to DNA‐synthesis in immature cells, since the percentage of such cells with a reduced DNA content was also significantly (P = 0.0424‐0.0002) increased. The error of the method expressed as the variance of multiple measurements has been found to be 0.0002‐0.0004. A staining error has been found for some hydrolysis times, but not for times between 60 and 120 minutes. A measuring error was found for an average of 1.38 to 3.38% of the cells.
DDAVP in acquired hemophilia a: Case report and review of the literature
Authors: Mudad Raja , Kane William H. 
Published: February 2007

AbstractOne patient with an acquired factor VIII inhibitor is reported in which an acute lower intestinal hemorrhage was successfully managed using Desmopressin (DDAVP). The patient initially had a factor VIII level of 10% with a inhibitor titer of 1.9 Bethesda units. Following administration of DDAVP the factor VIII level rose to 86% and there was a decrease in the number and volume of bloody stools. The inhibitor disappeared following treatment with corticosteroids, however the patient ultimately expired due to complications of ischemic colitis. This case and 21 previously reported cases of acquired hemophilia treated with DDAVP are reviewed. The data support a role for DDAVP in the treatment of non life threatening hemorrhage in patients with acquired hemophilia and low titer factor VIII inhibitors (<5 Bethesda units or factor VIII≧5%).
Observation of serum estradiol testosterone and immune function in aplastic anemia
Authors: Cao Qingxue , Liu Jianbin 
Published: February 2007

AbstractLetters and correspondence submitted for possible publication must be identified as such. Text length must not exceed 500 words and five bibliographic references. A single concise figure or table may be included if it is essential to support the communication. Letters not typed double‐spaced will not be considered for publication. Letters not meeting these specifications will not be returned to authors. Letters to the Editor are utilized to communicate a single novel observation or finding. Correspondence is to be used to supplement or constructively comment on the contents of a publication in the journal and cannot exceed the restrictions for Letters to the Editor. The Editor reserves the right to shorten text, delete objectional comments and make other changes to comply with the style of the journal. Permission for publication must be appended as a postscript. Submissions must be sent to Marcel E. Conrad, M.D., Associate Editor, American Journal of Hematology, USA Cancer Center, Mobile, Alabama 36688 to permit rapid consideration for publication.
Consequences of chronic hepatitis C: A review article for the hematologist
Authors: Aledort Louis M. 
Published: February 2007

AbstractThe hepatitis C virus (HCV) has been cloned, and assays capable of detecting antibody to HCV recombinant proteins (anti‐HCV) have been developed. Concurrent with the cloning and development of the anti‐HCV screening tests, trials with interferon alfa‐2b have documented biochemical and histologic improvement in the indices of hepatitis C and non‐A, non‐B (NANB) in patients who were chronically infected. Subsequently, the anti‐HCV assays and interferon alfa‐2b have become clinically available. These new detection and treatment modalities can now be used in the management of hemophilics and other chronically transfused patients who bear great risk for blood‐borne infections and manifest signs of chronic hepatitis. © 1993 Wiley‐Liss, Inc.
Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia
Authors: Okumura Hirokazu , Nakamura Shinobu , Ohtake Shigeki , Yoshida Takashi , Kobayashi Kazumi , Okabe Yohko , Matano Sadaya , Kyohda Katsunori , Matsuda Tamotsu 
Published: February 2007

AbstractA 47‐year‐old woman was diagnosed with acute myelomonocytic leukemia (AMMoL) and was treated with combination chemotherapy. After one cycle of remission induction therapy, she entered into complete remission and then received three cycles of consolidation therapy. A month after the last consolidation therapy, she was diagnosed with having the complication of chemotherapy‐related HUS (C‐HUS). The C‐HUS improved after initiation of plasma exchange and antiplatelet therapy. In the present case, it seems that the antileukemic agents might play an important role in the development of C‐HUS. © 1993 Wiley‐Liss, Inc.
Dapsone for autoimmune thrombocytopenic purpura
Authors: Godeau Bertrand , Oksenhendler Eric , Bierling Philippe 
Published: February 2007

AbstractTwenty‐one human immunodeficiency virus (HIV)‐free and six HIV‐infected adults with autoimmune thrombocytopenic purpura (AITP) were treated with dapsone (100 mg/day). A response was observed in 13 patients (median platelet count before 25 × 109/L, range 3–49; after 109 × 109/L, range 69–241). Thrombocytopenia recurred in four of the responders in whom dapsone was discontinued. No response was observed in 12 patients. Dapsone had to be withdrawn after two weeks of treatment in the remaining two patients and after six to eight weeks in three other patients due to intolerance. No serious hematological complications were observed. These results confirm that dapsone is a safe, inexpensive, and effective treatment of AITP. © 1993 Wiley‐Liss, Inc.
Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
Authors: Wada Hideo , Mori Yoshitaka , Kaneko Toshihiro , Wakita Yoshihiro , Nakase Tutomu , Minamikawa Kouzou , Ohiwa Michiaki , Tamaki Shigehisa , Tanigawa Motoaki , Kageyama Sinichi , Deguchi Katsumi , Nakano Takeshi , Shirakawa Shigeru , Suzuki Koji 
Published: February 2007

AbstractHypercholesterolemia is associated with an increased incidence of vascular complications. To assess the actual degree of activation of coagulation systems and vascular disorders in hypercholesterolemia, plasma levels of vascular endothelial cell markers, such as thrombomodulin (TM), tissue‐type plasminogen activator, plasminogen activator inhibitor‐l (PAl‐l), and von Willebrand factor, were measured in 51 patients with hypercholesterolemia. We also investigated the effects of Pravastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, on plasma lipid, lipoprotein a, and hemostatic markers. The mean plasma levels of thrombin‐antithrombin III complex (TAT), fibrinopeptide A (FPA), TM, and PAl‐I were significantly elevated in hypercholesterolemia. Of the hemostatic markers, only TM was significantly increased in patients with ischemic heart diseases (IHD). The mean concentration of total cholesterol and levels of TAT, FPA, PAI‐I, and TM were significantly reduced after the Pravastatin treatment. The PIC/TAT ratio was significantly increased in non‐IHD patients after treatment, this was not the case in IHD patients. These findings suggested the presence of a thrombogenic state and vascular endothelial cell disorders in hypercholesterolemia; such a state might well be related to hypofibrinolysis. © 1993 Wiley‐Liss, Inc.
Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family
Authors: Sano Masayuki , Saito Hidehiko , Shimamoto Yoshinori , Sugiura Isamu , Ohtsubo Haruhiko , Kohda Hiromu , Yamaguchi Masaya 
Published: February 2007

AbstractWe report a 28‐year‐old‐Japanese male who had a skin tumor derived from variant type xeroderma pigmentosum (XP), combined with factor XI (FXI) deficiency and type IIB von Willebrand's disease (vWd). The patient had abnormal bleeding history on tooth extraction. FXI clotting activity (FXI:C) and antigen (FXI:Ag) were remarkably decreased (<0.01 U/ml, <0.02 U/ml, respectively). Factor VIII (FVIII) clotting activity, von Wiliebrand factor antigen (vWf :Ag), and ristocetin cofactor (RCoF) were 0.43 U/ml, 45%, and 57%, respectively. Ristocetin‐induced platelet agglutination (RIPA) revealed hyper‐aggregation compared with a normal control. Multimeric composition of vWf in plasma showed a reduction in high molecular weight forms. The family study revealed two other subjects with ho‐mozygous hereditary FXI deficiency and vWd, and five subjects with heterozygous FXI deficiency. The relationship between FXI deficiency and vWd is discussed and previously reported cases are reviewed. © 1993 Wiley‐Liss, Inc.
Inversion of chromosome 16 and eosinophilia in refractory anemia with ring sideroblasts: Report of a case
Authors: Inaba Tohru , Shimazaki Chihiro , Inaba Eiko , Hirata Toshiyuki , Ashihara Eishi , Ohkawa Katsunori , Oku Naritoshi , Goto Hideo , Murakami Satoshi , Fujita Naohisa , Misawa Shinichi , Nakagawa Masao 
Published: February 2007

AbstractA 72‐year‐old male who was admitted to our hospital with severe anemia was diagnosed as refractory anemia with ring sideroblasts (RARS), according to the French‐American‐British (FAB) classification of myelodysplastic syndromes (MDS). The patient showed persistent eosinophilia with no definite signs of either allergy or a parasitic infection. Chromosomal analysis of bone marrow cells revealed inv(16)(p13q22), a known characteristic of M4Eo acute myeloid leukemia (AML) in the FAB classification.This patient didn't exhibit leukemic transformation during his 20‐month clinical course, nor was any found at autopsy. Therefore, this is the first case of RARS to speculate that the chromosomal characteristic inv(16)(p13q22) might be specific for eosinophilia rather than AML. © 1993 Wiley‐Liss, Inc.
Characterization of nondeletion α‐thalassemia mutations in the Greek population
Authors: Traeger‐Synodinos Joanne , Kanavakis Emmanuel , Tzetis Maria , Kattamis Antonios , Kattamis Christos 
Published: February 2007

Abstractα‐Thalassemia is usually due to deletions within the α‐globin gene cluster, leading to loss of function of one (‐α) or both [‐(α) or –] α‐globin genes. Nondeletion mutations (denoted ααT or αTα) are less frequent and in Greece are not well defined. We report the analysis of 16 nondeletion α‐thalassemia chromosomes using a polymerase chain reaction method to amplify specifically the α2‐globin gene, which was subsequently screened using ASO hybridization or restriction enzyme analysis for four mutations already characterized in other Mediterranean and Middle Eastern populations. Of the 16 nondeletion chromosomes, nine had the polyadenylation signal mutation (αPolyAα), two the IVSI 5′ pentanucleotide deletion (αHphα), two the Hb Icaria mutation (αicα), and one the initiation codon mutation (αNcoα). In two, the defects are still undefined. These findings show that nondeletion α‐thalassemia in Greece is heterogeneous and that the most frequent mutation (accounting for >50%) is the polyadenylation signal mutation, which to date was most commonly found in the Saudi Arabian population. © 1993 Wiley‐Liss, Inc.
Graft versus host anti‐Rho(D) following minor Rh‐incompatible orthotopic liver transplantation
Authors: Lee Jong‐Hoon , Mintz Paul D. 
Published: February 2007

AbstractHemolysis caused by ABO antibodies after ABO‐compatible, nonidentical solid organ transplantation has been previously reported. The passenger B lymphocytes within the donor organ presumably generate an acute, primarily red cell‐directed graft vs. host (GVH) response. Graft survival may also be compromised. GVH Rh antibodies have also been described, primarily in renal transplants. Only three cases, two only in abstract form, have been reported thus far describing GVH Rh antibodies in liver transplant patients, to which we add a fourth. A 62‐year‐old blood group A Rho(D)‐positive woman with cirrhosis underwent orthotopic liver transplantation from a group A Rho(D)‐negative, previously Rho(D)‐sensitized donor and subsequently developed acute, self‐limited hemolysis requiring four units of packed red cells. Anti‐Rho(D) was identified in both serum and red cell eluate. An antibody detection test, identification, and assessment of the antibody reactivity score from the pretransplant donor specimen may identify patients at risk for hemolysis due to GVH Rh antibodies. © 1993 Wiley‐Liss, Inc.
Human parvovirus B19 infection in bone marrow transplantation patients
Authors: Azzi A. , Fanci R. , Ciappi S. , Zakrzewska K. , Bosi A. 
Published: February 2007

AbstractWe report the results of a survey of parvovirus B19 infection carried out with the aim to evaluate the frequency and the role of this infection in bone marrow transplant (BMT) recipients, as it is known that B19 virus can persist in clinical circumstances of immunodeficiency. Fifty‐one patients subjected to BMT in the Bone Marrow Transplantation Center of Florence were enrolled in this study. Immunological and virological indications of B19 infection were tested weekly during the stay in hospital. A high rate of seroconversion or B19 antibody rise was observed, but, in absence of B19 IgM or B19 DNA presence, this result seems to be attributable to a passive immunization, rather than to a recent viral infection. In these 51 patients, as well as in 59 others not included in this study, clinical manifestations imputable to B19 infection have never been observed. It is possible that the isolation measures and the intravenous immunoglobulins (IVIG) administration may contribute in preventing B19 infection in the BMT recipients at least until the hospital discharge. © 1993 Wiley‐Liss, Inc.
Hypofibrinolysis in patients with hypercoagulability: The roles of urokinase and of plasminogen activator inhibitor
Authors: Lau Herbert K. F. , Teitel Jerome M. , Cheung To , Kung Sam K. P. , Garvey M. Bernadette 
Published: February 2007

AbstractThe prevalence of abnormalities of fibrinolysis in patients with venous thromboembolism is as yet unknown. Defined abnormalities include congenital dysfunction and deficiency of plasminogen, and probably impaired plasminogen activation secondary to elevated levels of plasminogen activator inhibitor type 1 (PAI‐1) or to impaired release of tissue plasminogen activator (tPA). In this preliminary study, we analyzed plasma samples from 21 patients for whom an investigation for possible thrombophilia was requested. Twenty of the patients had venous thromboembolism, and one had arterial thrombosis at an early age. Two patients had deficiency of protein C or protein S, but no other recognized biochemical disturbances related to thrombophilia were identified. Patient samples and plasma from 25 normal controls were assayed for tPA activity, PAI‐1 activity, and urokinase (uPA) activity and antigen. tPA activity and antigen were not significantly different in patients than in controls. PAI‐1 activity was significantly greater in patients (P < 0.0001). uPA activity was not different in the two groups. However, uPA antigen was significantly reduced in patients compared to controls (P = 0.001). These data suggest that hypofibrinolysis leading to a risk of thrombosis may be caused not only by elevated PAI‐1 activity but also by reduced total uPA concentration. © 1993 Wiley‐Liss, Inc.
Hemolytic anemia associated with lead poisoning from shotgun pellets and the response to succimer treatment
Authors: Aly Mahmoud H. , Kim Hugh C. , Renner Stephen W. , Boyarsky Andrew , Kosmin Martin , Paglia Donald E. 
Published: February 2007

AbstractSymptomatic lead poisoning with severe hemolytic anemia was observed in a patient with retained shot gun pellets. Surgical resection of the retained pellets and the use of a newer chelating agent, Succimer (2,3‐dimercaptosuccinic acid) successfully lowered blood lead level. Hemolytic anemia was associated with deficient erythrocyte pyrimidine 5′‐nucleotidase, and lowering of the lead level corrected the deficiency, suggesting that the enzyme deficiency is responsible for the hemolysis associated with lead poisoning. This case illustrates that retained lead pellets from shotgun wounds can cause severe lead poisoning. © 1993 Wiley‐Liss, Inc.
Polymorphic pattern of the (AT)x(T)y motif at −530 5′ to the β‐globin gene in over 40 patients homozygous for various β‐thalassemia mutations
Authors: Dimovski A. J. , Adekile A. D. , Divoky V. , Baysal E. , Huisman T. H. J. 
Published: February 2007

AbstractNucieotlde sequence analysis of the 5′ β‐globin gene flanking region has been carried out for numerous homozygous β‐thalassemla patients with difterent mutations and of various ethnic backgrounds. Four different rearrangements were found associated with numerous β‐thalassemia mutations. The (AT)x(T)y repeat motif at ‐530 showed polymorphic patterns among these patients as follows: All ten IVS‐II‐1 (G→A) chromosomes and the two with the ‐87 (C→G) mutation are associated with the (AT)9(T)5 rearrangement, while the 30 IVS‐I‐6 (T→C), the 16 codon 39 (C→T), the slx codon 8 (‐AA) chromosomes, and 12 chromosomes with different promoter mutations had the (AT)7(T)7 motif. Six chromosomes with the promoter mutation at position − 29 (A→ G) had the (AT)6(T)6 motif, while an (AT)5(T)4 motif appears characteristic for two IVS‐I‐5 (G→A and G→T). No direct association between any of the (AT)x(T)y arrangements and an increased γ gene expression [gγ and fetal hemoglobin (Hb F)] levels could be demonstrated, suggesting that variations In the (AT)x(T)y motif are common polymorphisms. © 1994 Wiley‐Liss, Inc.
Cytokine profile during high‐dose rhG‐CSF therapy in severe congenital neutropenia
Authors: Shitara Toshiji , Yugami Shin‐Ichiroh , Ijima Hiroko , Sotomatu Manabu , Kuroume Takayoshi 
Published: February 2007

AbstractThe effect of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) on cytokine profile was evaluated in a case of severe congenital neutropenia. The plasma levels of cytokines were measured before and during rhG‐CSF therapy. These included G‐CSF, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interleukin‐1α, in‐terleukin‐1 β, interleukin‐2 (IL‐2), interleukin‐3 (IL‐3), interleukin‐4, interleukin‐6 (IL‐6), and tumor necrosis factor‐α. Soluble Interleukin‐2 receptor (sIL‐2R) was measured serially during rhG‐CSF therapy. Lymphocyte subpopulations Including CD2, CD3, CD4, CD8, CD19, CD20, and CD25 were also measured, rhG‐CSF was administered once daily as a 30‐min infusion. The patient was treated with Increasing dose levels of 100,200,400, 800, and 1,600 μg/m2/day. The level of endogenous G‐CSF was elevated to 334 pg/ml before treatment and GM‐CSF, IL‐2, IL‐3, and IL‐6 were slightly elevated. Clinically, he showed a moderate response to a high dose of rhG‐CSF (1,600 μg/m2/day). Plasma levels of G‐CSF markedly Increased during therapy but plasma levels of other cytokines did not show significant changes during therapy and iymphocyte subpopulations did not significantly change. A drastic Increase in siL‐2R expression was observed after rhG‐CSF infusion and an Increase in siL‐2R expression occurred even before a major increase in granulocyte counts. These results showed that a high dose rhG‐CSF therapy may influence the cytokine network as judged by the increased slL‐2R expression. © 1994 Wiley‐Liss, Inc.
Autoimmune‐thrombocytopenia and sle in a patient with 5q‐anomaly and deletion of the c‐fms oncogene
Authors: Jaeger Ulrich , Panzer Simon , Bartram Claus , Haas Oskar , Volc‐Platzer Beatrix , Graninger Wolfgang , Geissler Klaus , Radaszkiewicz Thaddaeusz , Lechner Klaus 
Published: February 2007

AbstractAutoimmune‐thrombocytopenia was the striking feature in a patient with typical clinical symptoms of systemic lupus erythematosus (SLE), complement C4 deficiency, and positive lupus serology. However, myelodysplasia was found in the bone marrow and chromosome analysis revealed a deletion of the long arm of chromosome 5 (5q‐ anomaly), which was confirmed by a hemitygosity for the c‐fms oncogene (CSF‐1‐receptor) on Southern blot. Autoimmune phenomena reported In conjunction with myelodysplastic syndromes (MDS), e.g., an elevation of antinuclear antibodies, are usually regarded as nonspecific. This case report suggests that SLE can occur in patients with MDS and that a concomitant autoimmune‐thrombocytopenia may mask the typical signs of the 5q‐ syndrome. © 1994 Wiley‐Liss, Inc.
Laboratory monitoring of warfarin therapy in Utah
Authors: Garr Susan B. , Rodgers George M. 
Published: February 2007

AbstractAccurate laboratory monitoring of oral anticoagulation has been emphasized as an important factor in providing safe and effective therapy for patients with thromboembolism. However, recent reports indicate that coagulation laboratories may not be providing optimal clinical information to clinicians who treat these patients. We surveyed all hospltal coagulation laboratories in Utah to determine their format for reporting prothrombin time results in patients receiving oral anticoagulants. We found that less than 50% of laboratories used the reliable reporting format, i.e., the interational Normalized Ratio (INR), and that many of the laboratories using the INR format may be reporting incorrect values. Our survey also found a significant lack of interest by physicians in requesting that their laboratories adopt reliable reporting methods. These results indicate a substantial lack of understanding by laboratories and clinicians of the importance of using reliable methods to monitor oral anticoagulation. Significant educational efforts will be required to correct this problem. © 1994 Wiley‐Liss, Inc.
Transgenic mouse model of pharmacologic induction of fetal hemoglobin: Studies using a new ribonucleotide reductase inhibitor, didox
Authors: Pace B. S. , Elford H. L. , Stamatoyannopoulos G. 
Published: February 2007

AbstractEvaluation of pharmacologic agents that stimulate fetal hemoglobin production has been done mainly in baboons and macaques. We investigated whether results in transgenic mice can predict the stimulation of fetal hemoglobin in primates, by testing γ globin induction in response to a new rlbonucleotide reductase inhibitor, Didox. A transgenic mouse line carrying the human Aγ gene linked to a locus control region cassette was used. Treatment of transgenic mice with Didox resulted in induction of γ gene expression as documented by an Increase in F reticulocytes and F cells and an elevation of γ/γ + β biosynthetic ratio. Similarly, administration of Didox to a baboon in the nonanemic and chronically anemic state resulted In induction of γ gene expression as shown by increases in F reticuiocytes, F cells, and Hb F. These results suggest that the μLR‐Aγ transgenic mice can be used to screen new pharmacologic compounds for γ globin inducibillty. © 1994 Wiley‐Liss, Inc.